Beam Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

August 06, 2025

Simply Wall St

NasdaqGS:BEAM 1 Year Share Price vs Fair Value

Explore Beam Therapeutics's Fair Values from the Community and select yours

Beam Therapeutics (NASDAQ:BEAM) Second Quarter 2025 Results

Key Financial Results

Revenue: US$8.47m (down 28% from 2Q 2024).
Net loss: US$102.3m (loss widened by 12% from 2Q 2024).
US$1.00 loss per share.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

earnings-and-revenue-growth — NasdaqGS:BEAM Earnings and Revenue Growth August 6th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Beam Therapeutics EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 36%. Earnings per share (EPS) exceeded analyst estimates by 7.9%.

Looking ahead, revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 6.2% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Beam Therapeutics, and understanding these should be part of your investment process.

Valuation is complex, but we're here to simplify it.

Discover if Beam Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.